Molecular assessment of the fecal microbiota in healthy cats and dogs before and during supplementation with fructo-oligosaccharides (FOS) and inulin using high-throughput 454-pyrosequencing

Jose F Garcia-Mazcorro Corresp., 1, 2, Jose R Barcenas-Walls 3, Jan S Suchodolski 4, Jörg M Steiner 4

1 Gastrointestinal Laboratory, Department of Small Animal Clinical Sciences, College of Veterinary Medicine & Biomedical Sciences, Texas A&M University, College Station, Texas, United States
2 Faculty of Veterinary Medicine, Universidad Autónoma de Nuevo León, General Escobedo, Nuevo Leon, Mexico
3 Center for Research and Development in Health Sciences (CIDICS), Genomics Unit, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico
4 Gastrointestinal Laboratory, Department of Small Animal Clinical Sciences, College of Veterinary Medicine & Biomedical Science, Texas A&M University, College Station, Texas, United States

Corresponding Author: Jose F Garcia-Mazcorro
Email address: josegarcia_mex@hotmail.com

Prebiotics are selectively fermentable dietary compounds that result in changes in the composition and/or activity of the intestinal microbiota, thus conferring benefits upon host health. In veterinary medicine, commercially available products containing prebiotics have not been well studied with regard to the changes they trigger on the composition of the gut microbiota. This study evaluated the effect of a commercially available nutraceutical containing fructo-oligosaccharides (FOS) and inulin on the fecal microbiota of healthy cats and dogs when administered for 16 days. Fecal samples were collected at two time points before and at two time points during prebiotic administration. Total genomic DNA was obtained from fecal samples and 454-pyrosequencing was used for 16S rRNA gene bacterial profiling. The linear discriminant analysis (LDA) effect size (LEfSe) method was used for detecting bacterial taxa that may respond (i.e., increase or decrease in its relative abundance) to prebiotic administration. Prebiotic administration was associated with a good acceptance and no side effects (e.g. diarrhea) were reported by the owners. A low dose of prebiotics (50 mL total regardless of body weight with the end product containing 0.45% of prebiotics) revealed a lower abundance of Gammaproteobacteria and a higher abundance of Veillonellaceae during prebiotic administration in cats, while Staphylococcaceae showed a higher abundance during prebiotic administration in dogs. These differences were not sufficient to separate bacterial communities as shown by analysis of weighted UniFrac distance metrics. A predictive approach of the fecal bacterial metagenome using PICRUSt also did not reveal differences between the period before and during prebiotic administration. A second trial using a higher dose of prebiotics (3.2 mL/kg
body weight with the end product containing 3.1% of prebiotics) was tested in dogs and revealed a lower abundance of *Dorea* (family Clostridiaceae) and a higher abundance of *Megamonas* and other (unknown) members of Veillonellaceae during prebiotic administration. Again, these changes were not sufficient to separate bacterial communities or predicted metabolic profiles according to treatment. A closer analysis of bacterial communities at all time-points revealed highly individualized patterns of variation. This study shows a high interindividual variation of fecal bacterial communities from pet cats and dogs, that these communities are relatively stable over time, and that some of this variation can be attributable to prebiotic administration, a phenomenon that may be affected by the amount of the prebiotic administered in the formulation. This study also provides insights into the response of gut bacterial communities in pet cats and dogs during administration of commercially available products containing prebiotics. More studies are needed to explore potentially beneficial effects on host health beyond changes in bacterial communities.
Molecular assessment of the fecal microbiota in healthy cats and dogs before and during supplementation with fructo-oligosaccharides (FOS) and inulin using high-throughput 454-pyrosequencing

Jose F Garcia-Mazcorro¹, Jose R. Barcenas-Walls², Jan S. Suchodolski¹ and Jörg M. Steiner¹

¹Gastrointestinal Laboratory, Department of Small Animal Clinical Sciences, College of Veterinary Medicine & Biomedical Sciences, Texas A&M University, College Station, Texas, USA
²Center for Research and Development in Health Sciences (CIDICS), Genomics Unit, Universidad Autonoma de Nuevo Leon (UANL), Monterrey, Nuevo León, México

¹Current address: Faculty of Veterinary Medicine, Universidad Autónoma de Nuevo León, General Escobedo, Nuevo León, México

Corresponding authors

Jose F. Garcia-Mazcorro, jose.garciamzc@uanl.edu.mx
Abstract

Prebiotics are selectively fermentable dietary compounds that result in changes in the composition and/or activity of the intestinal microbiota, thus conferring benefits upon host health. In veterinary medicine, commercially available products containing prebiotics have not been well studied with regard to the changes they trigger on the composition of the gut microbiota.

This study evaluated the effect of a commercially available nutraceutical containing fructooligosaccharides (FOS) and inulin on the fecal microbiota of healthy cats and dogs when administered for 16 days. Fecal samples were collected at two time points before and at two time points during prebiotic administration. Total genomic DNA was obtained from fecal samples and 454-pyrosequencing was used for 16S rRNA gene bacterial profiling. The linear discriminant analysis (LDA) effect size (LEfSe) method was used for detecting bacterial taxa that may respond (i.e., increase or decrease in its relative abundance) to prebiotic administration. Prebiotic administration was associated with a good acceptance and no side effects (e.g., diarrhea) were reported by the owners. A low dose of FOS and inulin (50 mL total regardless of body weight with the end product containing 0.45% of prebiotics) revealed a significantly lower abundance of Gammaproteobacteria and higher abundance of Veillonellaceae during prebiotic administration in cats, while Staphylococcaceae showed a higher abundance during prebiotic administration in dogs. These differences were not sufficient to separate bacterial communities as shown by analysis of weighted UniFrac distance metrics. A predictive approach of the fecal bacterial metagenome using PICRUSt also did not reveal differences between the period before and during prebiotic administration. A second trial using a higher dose of FOS and inulin (3.2 mL/kg body weight with the end product containing 3.1% of prebiotics) was tested in dogs and
revealed a lower abundance of *Dorea* (family Clostridiaceae) and a higher abundance of *Megamonas* and other (unknown) members of Veillonellaceae during prebiotic administration. Again, these changes were not sufficient to separate bacterial communities or predicted metabolic profiles according to treatment. A closer analysis of bacterial communities at all time-points revealed highly individualized patterns of variation. This study shows a high interindividual variation of fecal bacterial communities from pet cats and dogs, that these communities are relatively stable over time, and that some of this variation can be attributable to prebiotic administration, a phenomenon that may be affected by the amount of the prebiotic administered in the formulation. This study also provides insights into the response of gut bacterial communities in pet cats and dogs during administration of commercially available products containing prebiotics. More studies are needed to explore potentially beneficial effects on host health beyond changes in bacterial communities.

**INTRODUCTION**
The digestive tract of cats and dogs is inhabited by millions of microorganisms (especially bacteria) that exert a positive and vital effect on host health (Suchodolski 2011). A large number of articles are steadily being published showing the extent (e.g. in microbial composition) and consequences (e.g. relationship of specific microbes with persistence of clinical signs) of this symbiosis in health and during a variety of disease states and conditions such as obesity, gastrointestinal inflammation, and diarrhea (Deusch et al., 2015; Guard et al., 2015; Hand et al., 2013; Handl et al., 2013; Junginger et al., 2014; Kieler et al., 2016; Minamoto et al., 2014; Minamoto et al., 2015; Song et al., 2013; Suchodolski et al., 2015). These studies are supported by meta’omic analytic techniques (Morgan and Huttenhower, 2014) and powerful freely-available computational resources to analyze the generated data (Navas-Molina et al., 2013).

Humans and other mammals, such as cats and dogs, do not have all the necessary enzymes in their small intestinal tract that are capable of degrading several types of plant fibers (Flint et al., 2012). Upon consumption and after traveling throughout the small intestine, some types of these non-digestible fibers (e.g. fructo- oligosaccharides) are fermented by the bacterial microbiota in the colon thus exerting a positive effect on the abundance of beneficial bacterial groups (e.g. Lactobacillus and Bifidobacterium), intestinal motility, epithelial cellular integrity, and microbial biochemical networks (Scott et al., 2015). Interestingly, prebiotics appear to also influence distant sites such as bones and skin apparently through an increase of beneficial bacteria in the gut and derived fermentation products from this increase reaching target cells (Collins and Reid, 2016). Several research studies have shown beneficial effects associated with the consumption of fiber on gut microbiota and overall health (e.g. improvement of gut barrier integrity) in humans and other vertebrates (Montalban-Arques et al., 2015).
Prebiotics are non-digestible carbohydrates such as fructo-oligosaccharides (FOS), galacto-oligosaccharides (GOS) and inulin that are currently added to several commercial foods for cats and dogs. Studies have shown an effect of these ingredients on fecal microbial composition, nutrient digestibility, and short-chain fatty acid concentrations, particularly in dogs (Patra 2011; Schmitz and Suchodolski, 2016; de Godoy et al., 2013). Domestic cats are obligate carnivores but several studies support the hypothesis that microbial fermentation inside the distal gut is significant and beneficial to the host (Rochus et al., 2014). However, most of the published studies have researched the effect of natural prebiotics (with and without processing, e.g. potato fiber, see Panasevich et al., 2015) as opposed to commercial preparations containing these ingredients. This generates an important gap in the prebiotic literature because commercial prebiotic preparations are sold all over the world, thus exposing cats and dogs of all ages and with various clinical conditions to its potential effects on gut microbial ecology and health. Moreover, prebiotics should theoretically increase the abundance of certain bacterial groups (e.g. Lactobacillus and Bifidobacterium) in the gut in order to be considered a prebiotic, given current definitions of these dietary compounds (Gibson et al., 2010). The objective of this study was to evaluate the effect of a commercially available product containing prebiotics on fecal bacterial composition of clinically healthy cats and dogs. The results of this work show statistical significant differences in several bacterial groups that can be attributed to prebiotic administration. This study also provides relevant insights into the uniqueness of baseline fecal bacterial populations and their highly individualized variability over time and response upon prebiotic administration in pet cats and dogs.
METHODS

Ethics
All experimental procedures were authorized by the Animal Care and Use Committee (AUP 2011-160) and the Clinical Research Review Committee at Texas A&M University (CRRC 10-14) and written informed client consent was obtained from the owners of all enrolled animals. Inclusion criteria included healthy (i.e. lack of clinical signs and good physical condition) non-obese client-owned pet cats and dogs. Owners were indicated to feed their pets as usual without any supplement such as probiotics, prebiotics or vitamins. Exclusion criteria included abnormal serum parameters that could indicate subclinical abnormalities. An empty copy of the animal owners consent form is available as Supplemental File.

Trial 1 (cats and dogs)
Clinically healthy client-owned and non-obese cats (n=12) and dogs (n=12) were enrolled (Table 1). Regardless of body weight, owners were instructed to feed 50 mL (containing 225 mg of FOS and inulin) of Viyo Veterinary® (proprietary mixture of vegetable and meat by-products, oils, vitamins and minerals containing 0.45% of prebiotics or 4,500 mg per kg in the end product) once per day for 16 days (this was the original dose recommended by the company). Although we deliberately did not control for the amount of food eaten per day, for a 10 kg dog eating 200 g of food per day this original dose would represent approximately 0.1% of dry matter intake. It should be noted that this prebiotic percentage of dry matter intake decreases proportionally to total dry matter intake. For example, for a 20 kg dog eating 400 g of food this original dose of 50 mL would only represent 0.06% prebiotic on a dry matter basis. Fecal samples were collected by the owners at two time points before prebiotic administration (8 days and 1 day before initiation
of prebiotic administration) and again at two time points after initiation of prebiotic administration (days 8 and 16 after initiation of prebiotic administration) (see Figure 1 for a timeline of our experimental design). Fecal samples were collected into special fecal sample tubes (provided), placed into zip-lock bags (provided) and frozen as soon as possible after collection. Samples were stored in the freezer until brought to our laboratory within 1-8 hours, where they were stored at -20 °C until DNA extraction. The administration of 50 mL of Viyo Veterinary® daily for 16 days was the original dose recommended by the company in an effort to improve health by a modification in the gut microbiota (main objective of this current study).

**Trial 2 (dogs only)**

Clinically healthy client-owned non-obese dogs (n=10) were enrolled (Table 2). Five of these dogs also participated in trial 1 (Trial 2 started approximately 9 months after Trial 1, therefore there is no risk on carryover effects). Owners were instructed to feed 3.2 ml/kg bodyweight (each mL containing 31 mg of FOS and inulin) of an especially formulated preparation of Viyo Veterinary® (containing 3.1% of prebiotics or 31,000 mg per kg in the end product) once per day for 16 days. The new formula was designed in an effort to reach high enough levels of prebiotics in the overall dry matter consumed that would be expected to have an impact on the intestinal microbiota in all dogs without reaching unfeasible amounts (in mL) of the product. For example, a 10 kg dog eating 200 g of food per day would need to consume 32 mL of the product (equating to 992 mg of prebiotics) and this new dose would represent approximately 0.5% of dry matter intake, while a 20 kg dog eating 400 g of food per day would need to consume 60 mL of the product (equating to 1860 mg of prebiotics) and this new dose would also represent approximately 0.5% of dry matter intake. Similarly to trial 1, fecal samples were collected at two
time points before prebiotic administration (8 days and 1 day before initiation of prebiotic
administration) and at two time points after initiation of prebiotic administration (days 8 and 16
after initiation of prebiotic administration) (Figure 1).

**Questionnaire**

All pet owners (trials 1 and 2) were provided with a questionnaire to record the following
parameters during the study period: acceptance of the prebiotic, attitude, appetite, drinking
behavior, defecation frequency, borborygmus, flatulence, as well as volume, consistency, and
color of feces (Supplemental File). This questionnaire has been used in other studies from our
research group (*Rutz et al.*, 2004).

**DNA extraction and 16S bacterial profiling**

A bead-beating phenol-chloroform based-method was utilized to isolate total genomic DNA
from all fecal samples as described elsewhere (*Suchodolski et al.*, 2005). Primers specific for 16S
rRNA genes were used to amplify the variable V4-V5 region as described previously
(*Suchodolski et al.*, 2009). Fecal bacterial communities were evaluated using 454-
pyrosequencing before and during prebiotic administration using a bacterial tag-encoded FLX-
titanium 16S rRNA gene amplicon pyrosequencing (bTEFAP) as described previously for canine
and feline fecal samples (*Garcia-Mazcorro et al.*, 2011; *Handl et al.*, 2011). All sequences with
their corresponding metadata information is freely available in the Sequence Read Archive at the
NCBI (SRP071082).

**Sequence analysis**
The open-source freely available bioinformatics pipeline Quantitative Insights into Microbial Ecology (QIIME) v. 1.8 was used to perform microbiome analysis from raw 16S DNA sequencing data using default scripts unless otherwise noted (Caporaso et al., 2010; Navas-Molina et al., 2013). The split_libraries.py was used to perform quality filtering and demultiplexing (i.e. assignment of reads to samples). Operational Taxonomic Units (OTUs) were assigned using two different approaches. First using UCLUST v.1.2.22 (Edgar 2010) using an open reference script (pick_open_reference_otus.py) in QIIME for alpha and beta diversity. Note that this algorithm does not necessarily discard sequences that do not match the reference 16S database, thus allowing for an accurate OTU representation. Second, using a closed reference algorithm (pick_closed_reference_OTUs.py) for further analysis using Phylogenetic Investigation of Communities by Reconstruction of Unobserved States (PICRUSt) (Langille et al., 2013). The GreenGenes 13_5 97% OTU representative 16S rRNA gene sequences was used as the reference sequence collection (DeSantis et al., 2006). Both weighted and unweighted UniFrac distances were used to investigate clustering of microbial communities (Lozupone and Knight, 2005; Lozupone et al., 2007).

### Statistical analysis

The linear discriminant analysis (LDA) effect size (LEfSe) method (Segata et al., 2011) was used to find organisms that could explain the differences in bacterial communities between the time periods before and during prebiotic administration. This method uses non-parametric tests and has been shown to be able to capture microbial taxa associated with class variables in several studies from our research groups (Garcia-Mazcorro et al., 2016; Minamoto et al., 2015). The ANOSIM and Adonis tests included in the compare_categories.py QIIME script were used to
determine whether the grouping of samples (i.e. microbial communities) accordingly to
treatment period (i.e. before and during prebiotic administration) is statistically significant also in
QIIME. An alpha of 0.05 was considered to reject null hypotheses.

RESULTS
Viyo Veterinary® was well accepted (i.e. all except two cats in trial 1 and one dog in trial 2 had a
good or excellent acceptance of the product at all time points during administration of the
product, as perceived by the owners). No negative side effects from consuming the prebiotic
preparation, such as vomiting, abdominal pain, lethargy, changes in fecal consistency, and/or
diarrhea were reported by the owners. Briefly, 96% of all time points either before or during
prebiotic in both trials were reported as normal or better than normal in all parameters measured
that contained normal as a category. As perceived by the owners, one cat in trial 1 had lose or
pulpy feces throughout the whole study period (i.e. before and during prebiotic), and one dog had
some flatulence also throughout the study (in fact, this dog also participated in trial 2 and was
also reported to present some flatulence during the whole study period). In trial 1 two cats
refused to consume the product and were therefore excluded from the study. Also in trial 1, two
dogs were excluded because of serum cobalamin and folate concentrations that were below the
lower limit of the reference interval (1 dog) or microfilaria identified in the blood during the
complete blood count (1 dog).

Trial 1 – cats
A total of 10 cats completed trial 1 (~4600 quality-filtered sequences per sample; average 442
nucleotides per sequence) (Table 1). Similarly to other studies (Handl et al., 2011), the fecal
microbiota of cats was dominated by Firmicutes (median: 93.5%, range: 54.5-99.8%) followed
by smaller proportions of Bacteroidetes (median: 3.4%, range: 0-37.1%) and other very low
abundant groups (Figure 2). Please note that each study reveals numbers and proportions of
different microbial taxa that are the result of a combination of factors such as primers for 16S
amplification, DNA extraction procedure, length of amplicon, reference sequence collection used
to assign taxonomy, and inter-individual variability. The fecal microbiota in cats showed less
intraindividual variability over time compared to interindividual variability (Figure 3).
Interestingly, cat number 2 (C2) and cat number 5 (C5) showed high increases in the relative
abundance of Lactobacillales (mostly *Lactobacillus* spp.) during prebiotic administration (Figure
3), which is noteworthy given the historical association of prebiotics with increased abundances
of lactic acid bacteria.

The LEfSe method showed that an unknown member of the family Veillonellaceae (order
Clostridiales within Firmicutes) was significantly increased during prebiotic administration, and
also that an unknown member of Gammaproteobacteria was decreased during prebiotic
administration (Figure 4). These changes, which involved samples from several individual cats
thus suggesting an effect of the prebiotic (Figure 4), were not sufficient to cause a significant
difference in bacterial communities using weighted UniFrac distances (Figure 5, please note that
the analysis of unweighted UniFrac distances revealed similar results). This lack of significance
is supported by high *p*-values in ANOSIM and Adonis tests (*p* > 0.5), even though these tests are
known to have very low specificity (i.e., these tests usually detect a difference in microbial
communities even when there is not necessarily a strong and clear separation in PCoA plots). A
predictive approach to investigate the functional microbiome using PICRUSt did not reveal any
significant difference between the period before and during prebiotic administration (Supplemental Files).

**Trial 1 – dogs**

A total of 10 dogs completed trial 1 (~4600 quality-filtered sequences per sample; average 442 nucleotides per sequence). One sample (dog number 11 or D11, day 8 during prebiotic administration) did not produce any sequence data and could not be used for analysis. Similarly to other studies (Handl et al., 2011), the fecal microbiota of dogs was dominated by Firmicutes (median: 93.2%, range: 70.2-98.8%) (Figure 2) with each dog also having unique patterns of fecal bacterial abundances showing stability over time (Figure 3). Two dogs (dog number 3, D3, and dog number 12, D12) showed high increases in the order Lactobacillales during prebiotic administration (Figure 3) although D12 did not show the same increase in this bacterial group in trial 2 (see Trial 2 below). Interestingly, another dog in trial 1 (dog number 7, D7) had very high abundances of Lactobacillales at baseline (before prebiotic administration) and these abundances decreased to near 0% at day 16 of prebiotic administration (Figure 3). The LEfSe method showed that an unknown member of Staphylococcaceae was higher during prebiotic administration, while the genus *Sutterella* (family Alcaligenaceae in the order Burkholderiales within the Betaproteobacteria) was higher (although less prevalent) before prebiotic administration (Figure 6). It is important to note that these differences were due to a few samples only (especially for Staphylococcaceae), which were nonetheless enough for the LEfSe method to detect a significant effect (Figure 6). Similarly to cats, these differences were not sufficient to significantly separate bacterial communities according to weighted UniFrac distances (Figure 7, unweighted UniFrac revealed similar results). Also similarly to what was observed in cats, a
predictive approach to investigate the functional microbiome did not reveal any significant
difference between the period before and during prebiotic administration in the dogs enrolled in
trial 1 (Supplemental Files).

**Trial 2 – dogs only**

Trial 2 was designed to explore the possibility that an increase in prebiotic content would result
in relevant changes in the fecal microbiota, with a focus on canine patients. A total of 10 dogs
completed trial 2 (~3200 quality-filtered sequences per sample; average 432 nucleotides per
sequence). The fecal microbiota was again dominated by Firmicutes although with much lower
proportions compared to all dogs in trial 1 (median: 78.5% in trial 2 vs. a median: 93.2% in trial
1) and with higher variability (range: 29.6-97.6% vs. 70.2-98.8% in trial 1) (Figure 8). The
reasons behind these differences in relative proportions and variability in the phylum Firmicutes
(and other bacterial groups) are unclear; for example, 5 dogs participated in both trials but these
dogs showed bacterial abundances and over time variability (Figure 9) that did not necessarily
reflect those abundances and variability in trial 1 (Figure 3). Actually, dog 12 (D12) participated
in both trials but only showed increases in Lactobacillales in trial 1 (this dog was coded as dog
number 9 or D9 in trial 2). Interestingly, one dog in trial 2 (dog number 7, D7) had near 0%
*Bifidobacterium* at both time points before prebiotic administration, an increase to 8.4% on day 8
after initiation of prebiotic administration, and a further increase to 25.9% on day 16 after
initiation of prebiotic administration (Figure 9). This same dog (D7, trial 2) also had a massive
increase of Lactobacillaceae from <1% before and on day 8 after initiation of prebiotic
administration to 35.2% on day 16 after initiation, and Turicibacteraceae, from 0% before
prebiotic administration to 49% and 15% on days 8 and 16 after initiation of prebiotic
administration, respectively (Figure 9). The LEfSe method showed a lower abundance of *Dorea* (family Clostridiaceae) and also higher abundances of *Megamonas* and other (unknown) members of Veillonellaceae (class Negativicutes within the Firmicutes) during prebiotic administration (Figure 10). These changes involved samples from several individuals and can therefore be considered associated with the prebiotic administration tested in trial 2 (Figure 10). Similarly to dogs in trial 1, these differences were not sufficient to significantly separate bacterial communities according to weighted or unweighted UniFrac distances, or to cause significant differences in the predicted functional microbiome (Supplemental Files).

**DISCUSSION**

Prebiotics are non-digestible dietary ingredients with suggested health-bearing properties that are included in several commercially available products for use in cats and dogs. Sound scientific evidence shows that prebiotics can exert a positive effect on vertebrate (including humans) health (*Montalban-Arques et al., 2015*), but this has not been well studied in veterinary medicine, especially with regards to products that are commercially available. This study evaluated the fecal bacterial microbiota in healthy cats and dogs that were supplemented with a commercial prebiotic formulation containing FOS and inulin.

Our results support the fact that each individual animal (including humans) carries a microbial community so specific that it resembles a fingerprint (*Suchodolski et al., 2005; Zoetendal et al., 1998*). In fact, research performed on the human microbiota has demonstrated the feasibility of microbiome-based identifiability of single individuals (*Franzosa et al., 2015*). While the factors associated with this uniqueness are a matter of debate, several studies in humans have shown that
host genetics exerts a great influence (Benson et al., 2010; Blekhman et al., 2015) although diet may indeed outweigh the effects of host genetic background (Dabrowska and Witkiewicz, 2016; Wu et al., 2011). This microbial uniqueness is particularly important to clinicians (both human and veterinary) because it also implies individualized responses to treatment (Topol 2014), for example to antibiotic administration (Dethlefsen et al., 2011; Igarashi et al., 2014; Suchodolski et al., 2009). Unfortunately, guidelines for prebiotic administration are often unclear (i.e., companies usually suggest the same dose regardless of body weight, age, clinical condition, etc.) and have not fully considered the uniqueness of each gut microbial ecosystem (Barzegari and Saei, 2012).

While the individuality of gut microbial communities with regard to their response to prebiotic administration is a relevant matter for daily clinical use of these increasingly utilized nutraceutical ingredients, very few studies have discussed the uniqueness of native bacterial communities in individual cats or dogs, their variability over time or during the course of particular treatments (Garcia-Mazcorro et al., 2012a,b; Ritchie et al., 2008; Suchodolski et al., 2005). In this study, two cats and two dogs showed increases in the relative abundance of Lactobacillales (Figure 3), suggesting that these animals are highly responsive individual to the prebiotic tested (at least with regards to Lactobacillales). Also in trial 1, one dog had very high abundances of Lactobacillales at baseline (i.e. before prebiotic) but showed a marked decrease to near 0% at day 16 of prebiotic administration (D7, Figure 3). While these results suggest a relationship between baseline bacterial populations and response to prebiotics, this phenomenon has received very little attention (Garcia-Mazcorro et al., 2011; Stecher et al., 2010; Arciero et al., 2010; Vitali et al., 2009). For example, Vitali et al. (2009) mention that the significant
increase of a bacterial group (i.e. *Lactobacillus helveticus*) after administration of a synbiotic (containing fructo-oligosaccharides, *L. helveticus* and *Bifidobacterium longum*) was directly linked to the low incidence of this group in the intestine of the human host, thus implying a potential relationship between the native bacterial groups and any other group that is being supplemented in the form of probiotics or that increases due to the presence of prebiotics. In support of this hypothesis, one dog in trial 2 (dog number 7, D7) had near 0% *Bifidobacterium* at baseline before prebiotic administration but showed a remarkable increase of this bacterial group on day 16 after initiation of prebiotic administration (Figure 9), suggesting that this dog may also be considered a highly responsive individual to the prebiotic tested. Overall, our results support the concept that the native microbiota in each individual cat or dog is unique and that this microbiota show highly individualized patterns of variation over time and during the course of prebiotic administration.

In addition to confirming the uniqueness of fecal microbiota in individual cats and dogs, this study also confirms previous observations about the minimal effects of low prebiotic dosages on the gut microbiota of healthy cats (*Sparkes et al., 1998; Kanakupt et al., 2011*) and dogs (*Willard et al., 1994; Willard et al., 2000; Barry et al., 2009; Vanhoutte et al., 2005*). This minimal effect of prebiotics on the gut microbial ecosystem is a common result when administering low doses of prebiotics (~1% of dry matter) but higher doses have been shown a potential to promote a more generalized effect of these ingredients in both cats (*Barry et al., 2010*) and dogs (*Middelbos et al., 2010*). However, conflicting results have been presented in the literature where different amounts of dietary fiber (0.5, 1, 2, 4, and 8%) was not associated with differences in the abundance of different microorganisms (*Faber et al., 2011*). Nonetheless, these and other similar
studies often lack sufficient representativeness with regard to the complex microbiota (i.e., most reports only studied one or a few organisms while hundreds of different microorganisms exist and cohabit the intestinal tract of cats and dogs) and some only used culture techniques, which are considered obsolete in contemporary studies of microbial ecology (Ritz 2007). Indeed, studies such as this current investigation that uses high-throughput sequencing allows investigating the majority of all bacterial groups at once, thus offering valuable insights to current prebiotic literature in small veterinary practice.

The dose of prebiotics offered to each individual patient is a matter of debate in human and veterinary medicine. There are at least three possible ways to administer prebiotics to cats and dogs in real-life. First, prebiotics can be offered as a fixed percentage of dry matter. Indeed, most well-controlled prebiotic papers in cats and dogs report the dose of prebiotics in percentage of dry matter intake, varying from 0% to 7% (Patra, 2011). A potential issue with this way of administering prebiotics (i.e. as percentage of dry matter) is that the amount of food consumed by a given pet cat or dog may vary substantially over time (e.g. accordingly to age) and among different animals (e.g. two dogs, each weighting 10 kg, may consume different amounts of food). Therefore, in a real-life scenario (not a controlled setting) two individual animals having the same body weight may consume different amounts of total prebiotics in their diets, not because of the prebiotic percentage of dry matter but because of the different amounts of food consumed. Second, a fixed amount of prebiotics can be offered regardless of dry matter intake, age, body weight, and all other specific characteristics of the animal. For example, 50 mL were offered in trial 1 regardless of body weight and the amount of food consumed each day to each cat and dog (please note that this was original dose provided by the company). This dose has the
disadvantage that the amount of prebiotic offered would decrease proportionally to the amount of food consumed. Finally, another way of administering prebiotics can be based on other parameters aside dry matter intake. For example, trial 2 was designed to equilibrate the amount of prebiotics for each dog, using a straightforward parameter (i.e. body weight). Interestingly, in this current study we report increases in important bacterial groups for gut health such as Veillonellacea (*Suchodolski et al., 2012*) only in trial 2. This discussion and the data generated by this current study may be relevant to guide other studies addressing the effect of products containing prebiotics offered to cats and dogs.

Our study evaluated a product that, together with other prebiotic formulations, are currently marketed to all breeds of cats and dogs of all ages, sizes and clinical conditions. Therefore, our study adds relevant information for the potential effect of commercial prebiotics. Nonetheless, there are at least five potential limitations of this study that are important to discuss for guiding future efforts in using prebiotics to improve intestinal health in cats and dogs. First, in this study we included a highly diverse group of animals, which may have influenced the response or lack thereof to prebiotic administration. The inclusion of a more homogeneous group of animals may have diminished this variability and therefore make the effect of prebiotic administration easier to detect. However, this is not always the case. For example, a recent study showed a minimal effect of potato fiber on the fecal microbiota of dogs using a homogeneous group of animals (all female with hound bloodlines and similar age and body weight) (*Panasevich et al., 2015*). In this study we deliberately included different dogs to mimic a real life scenario. Second, in this study we deliberately did not force the owners to feed a specific amount of food per day but instead we asked them to continue their regular feeding habits. This is important to investigate native
microbial communities and their fluctuations in ordinary pets, which are the ultimate consumers of nutraceuticals containing prebiotics. Third, in this study we only used one molecular technique (i.e., high-throughput sequencing) to assess the fecal microbiota, and other studies have shown that the results from this technique do not always correlate with the results of other molecular techniques such as fluorescent in situ hybridization (Garcia-Mazcorro et al., 2012). Nonetheless, other studies have shown that sequencing results correlate well with the results obtained from other molecular techniques such as quantitative real-time PCR (Minamoto et al., 2015; Panasevich et al., 2015). Fourth, commercial prebiotic formulations such as the one used in this study contains a mixture of ingredients aside the prebiotic component that makes it difficult to study the effect of the prebiotics independently. Lastly, in this study we only evaluated the bacterial microbiota but the fungal microbiota does indeed deserve investigation (Handl et al., 2011).

In summary, there is a potential beneficial effect of prebiotics to improve gut health in cats and dogs and this effect may be mediated by changes in the gut microbiota (Schmitz and Suchodolski, 2016). This study reinforces the notion that individual cats and dogs have a unique fecal microbiota, which is relatively stable over time and responds differently to dietary manipulation using prebiotics and possibly other dietary compounds. Also, this study shows that the consumption of up to 31 mg/kg body weight of prebiotics (a mixture of FOS and inulin) does not significantly change the abundance of most bacterial groups in feces of healthy dogs. Exceptions include bacterial groups such as Dorea, Megamonas, Sutterela, Veillonelaceae, Staphylococcaceae, and Gammaproteobacteria, which deserve attention because the changes observed in this study (although largely driven by individual responses) were not accompanied
by negative side effects. Veillonellaceae deserves particular attention because it showed increased abundances during prebiotic administration in cats (trial 1) and dogs (trial 2) in this current study and other studies have shown that this group is depleted in the duodenum of dogs with idiopathic inflammatory bowel disease (Suchodolski et al., 2012) and is highly responsive to dietary challenges (Bonder et al., 2016), including consumption of soluble corn fiber and polydextrose in humans (Hooda et al., 2012) and inulin in dogs (Beloshapka et al., 2013).

Importantly, this study was not performed in a controlled setting; therefore controlled studies with control of diet, environment and individual characteristics of the animals such as breed and age, may help to draw more conclusive evidence about the effect of prebiotics on the gut microbiota of pet cats and dogs. Our current study does not rule out other mechanisms by which the evaluated product may confer a health benefit to the host (e.g., increased production of short-chain fatty acids), but more studies are needed to prove this and to study in more detail the effect of this and other commercially available products containing prebiotics for cats and dogs.

Moreover, more studies are needed to explore potentially beneficial effects on host health beyond changes in bacterial communities such as increased expression of immunoregulators in the intestinal mucosa (e.g. cytokines).

REFERENCES

Arciero JC, Ermentrout GB, Upperman JS, Vodovotz Y, Rubin JE. 2010. Using a mathematical model to analyze the role of probiotics and inflammation in necrotizing enterocolitis. PLoS ONE 5:e10066 DOI 10.1371/journal.pone.0010066.

Barry KA, Hernot DC, Middelbos IS, Francis C, Dunsford B, Swanson KS, Fahey Jr. GC. 2009. Low-level fructan supplementation of dogs enhances nutrient digestion and
modifies stool metabolite concentrations, but does alter fecal microbiota populations. *Journal of Animal Science* **87**:3244-3252 DOI 10.2527/jas.2008-1659.

Barry KA, Wojcicki BJ, Middelbos IS, Vester BM, Swanson KS, Fahey Jr. GC. **2010**. Dietary cellulose, fructooligosaccharides, and pectin modify fecal protein catabolites and microbial populations in adult cats. *Journal of Animal Science* **88**:2978-2987 DOI 10.2527/jas.2009-2464.

Barzegari A, Saei AA. **2012**. Designing probiotics with respect to the native microbiome. *Future Microbiology* **7**:571-575 DOI 10.2217/fmb.12.37.

Beloshapka AN, Dowd SE, Suchodolski JS, Steiner JM, Duclos L, Swanson KS. **2013**. Fecal microbial communities of healthy adult dogs fed raw meat-based diets with or without inulin or yeast cell wall extracts as assessed by 454 pyrosequencing. *FEMS Microbiology Ecology* **84**:532-541 DOI 10.1111/1574-6941.12081.

Benson AK, Kelly SA, Legge R, Ma F, Jen Low S, Kim J, Zhang M, Lyn Oh P, Nehrenberg D, Hua K, Kachman SD, Moriyama EN, Walter J, Peterson DA, Pomp D. **2010**. Individuality in gut microbiota composition is a complex polygenic trait shaped by multiple environmental and host genetic factors. *Proceedings of National Academy of Sciences USA* **107**:18933-18938 DOI 10.1073/pnas.1007028107.

Blekhman R, Goodrich JK, Huang K, Sun Q, Bukowski R, Bell JT, Spector TD, Keinan A, Ley RE, Gevers D, Clark AG. **2015**. Host genetic variation impacts microbiome composition across human body sites. *Genome Biology* **16**:191 DOI 10.1186/s13059-015-0759-1.

Bonder MJ, Tigchelaar EF, Cai X, Trynka G, Cenit MC, Hrdlickova B, Zhong H, Vatanen T, Gevers D, Wijmenga C, Wang Y, Zhernakova A. **2016**. The influence of a short-
term gluten-free diet on the human gut microbiome. *Genome Medicine* **8**:45 DOI 10.1186/s13073-016-0295-y.

Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, Fierer N, Peña AG, Goodrich JK, Gordon JJ, Huttley GA, Kelley ST, Knights D, Koenig JE, Ley RE, Lozupone CA, McDonald D, Muegge BD, Pirrung M, Reeder J, Sevinsky JR, Turnbaugh PJ, Walters WA, Widmann J, Yatsunenko T, Zaneveld J, Knight R. 2010. QIIME allows analysis of high-throughput community sequencing data. *Nature Methods* **7**:335-36 DOI: 10.1038/nmeth.f.303.

Collins S, Reid G. 2016. Distant site effects of ingested prebiotics. *Nutrients* **8**:523 DOI 10.3390/nu8090523.

Dabrowska K, Witkiewicz W. 2016. Correlations of host genetics and gut microbiome composition. *Frontiers in Microbiology* **7**:1357 DOI 10.3389/fmicb.2016.01357.

de Godoy MR, Kerr KR, Fahey GC Jr. 2013. Alternative dietary fiber sources in companion animal nutrition. *Nutrients* **5**:3099-3117 DOI: 10.3390/nu5083099.

DeSantis TZ, Hugenholtz P, Larsen N, Rojas M, Brodie EL, Keller K, Huber T, Dalevi D, Hu P, Andersen GL. 2006. Greengenes, a chimera-checked 16S rRNA gene database and workbench compatible with ARB. *Applied Environmental Microbiology* **72**:5069-5072 DOI 10.1128/AEM.03006-05.

Dethlefsen L, Relman DA. 2011. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. *Proceedings of National Academy of Sciences USA* **108**:4554-4561 DOI 10.1073/pnas.1000087107.
Deusch O, O’Flynn C, Colyer A, Swanson KS, Allaway D, Morris P. 2015. A longitudinal study of the feline faecal microbiome identifies changes into early adulthood irrespective of sexual development. *PLoS ONE* **10**:e0144881 DOI 10.1371/journal.pone.0144881.

Edgar RC. 2010. Search and clustering orders of magnitude faster than BLAST. *Bioinformatics* **26**:2460-2461 DOI 10.1093/bioinformatics/btq461.

Faber TA, Hopkins AC, Middelbos IS, Price NP, Fahey Jr. GC. 2011. Galactoglucomannan oligosaccharide supplementation affects nutrient digestibility, fermentation end-product production, and large bowel microbiota of the dog. *J Animal Science* **89**:103-112 DOI 10.2527/jas.2010-3028

Flint HJ, Scott KP, Duncan SH, Louis P, Forano E. 2012. Microbial degradation of complex carbohydrates in the gut. *Gut Microbes* **3**:289-306 DOI 10.4161/gmic.19897.

Franzosa EA, Huang K, Meadow JF, Gevers D, Lemon KP, Bohannan BJ, Huttenhower C. 2015. Identifying personal microbiomes using metagenomic codes. *Proceedings of National Academy of Sciences USA* **112**:E2930-2938 DOI 10.1073/pnas.1423854112.

Garcia-Mazcorro JF, Dowd SE, Poulsen J, Steiner JM, Suchodolski JS. 2012a. Abundance and short-term temporal variability of fecal microbiota in healthy dogs. *MicrobiologyOpen* **1**:340-347 DOI 10.1002/mbo3.36.

Garcia-Mazcorro JF, Ivanov I, Mills DA, Noratto G. 2016. Influence of whole-wheat consumption on fecal microbial community structure of obese diabetic mice. *PeerJ* **4**:e1702 DOI 10.7717/peerj.1702.

Garcia-Mazcorro JF, Lanerie DJ, Dowd SE, Paddock CG, Grützner N, Steiner JM, Ivanek R, Suchodolski JS. 2011. Effect of a multi-species symbiotic formulation on fecal
bacterial microbiota of healthy cats and dogs as evaluated by pyrosequencing. *FEMS Microbiology Ecology* 78:542-554 DOI 10.1111/j.1574-6941.2011.01185.x.

Garcia-Mazcorro JF, Suchodolski JS, Jones KR, Clark-Price SC, Dowd SE, Minamoto Y, Markel M, Steiner JM, Dossin O. 2012b. Effect of the proton pump inhibitor omeprazole on the gastrointestinal bacterial microbiota of healthy dogs. *FEMS Microbiology Ecology* 80:624-636 DOI 10.1111/j.1574-6941.2012.01331.x.

Gibson GR, Scott KP, Rastall RA, Tuohy KM, Hotchkiss A, Dubert-Ferrandon A, Gareau M, Murphy EF, Saulnier D, Loh G, Macfarlane S, Delzenne N, Ringel Y, Kozianowski G, Dickmann R, Lenoir-Wijnkoop I, Walker C, Buddington R. 2010. Dietary prebiotics: current status and new definition. *Food Science & Technology Bulletin Functional Foods* 7:1-19 DOI 10.1616/1476-2137.15880.

Guard BC, Barr JW, Reddivari L, Klemashevich C, Jayaraman A, Steiner JM, Vanamala J, Suchodolski JS. 2015. Characterization of microbial dysbiosis and metabolomics changes in dogs with acute diarrhea. *PLoS ONE* 10:e0127259 DOI 10.1371/journal.pone.0127259.

Hand D, Wallis C, Colyer A, Penn CW. 2013. Pyrosequencing the canine faecal microbiota: breadth and depth of biodiversity. *PLoS ONE* 8:e53115 DOI 10.1371/journal.pone.0053115.

Handl S, Dowd SE, Garcia-Mazcorro JF, Steiner JM, Suchodolski JS. 2011. Massive parallel 16S rRNA gene pyrosequencing reveals highly diverse fecal bacterial and fungal communities in healthy dogs and cats. *FEMS Microbiology Ecology* 76:301-310 DOI:10.1111/j.1574-6941.2011.01058.x.
Handl S, German AJ, Holden SL, Dowd SE, Steiner JM, Heilmann RM, Grant RW, Swanson KS, Suchodolski JS. 2013. Faecal microbiota in lean and obese dogs. FEMS Microbiology Ecology 84:332-343 DOI 10.1111/1574-6941.12067.

Hooda S, Boler BM, Serao MC, Brule JM, Staeger MA, Boileau TW, Dowd SE, Fahey GC Jr, Swanson KS. 2012. 454 pyrosequencing reveals a shift in fecal microbiota of healthy adult men consuming polydextrose or soluble corn fiber. Journal of Nutrition 142:1259-1265 DOI 10.3945/jn.112.158766.

Igarashi H, Maeda S, Ohno K, Horigome A, Odamaki T, Tsujimoto H. 2014. Effect of oral administration of metronidazole or prednisolone on fecal microbiota in dogs. PLoS ONE 9:e107909 DOI 10.1371/journal.pone.0107909.

Junginger J, Lemensieck F, Moore PF, Schwittlick U, Nolte I, Hewicker-Trautwein M. 2014. Canine gut dendritic cells in the steady state and in inflammatory bowel disease. Innate Immunity 20:145-160 DOI 10.1177/1753425913485475.

Kanakupt K, Vester Boler BM, Dunsford BR, Fahey Jr. GC. 2011. Effects of short-chain fructooligosaccharides and galactooligosaccharides, individually and in combination, on nutrient digestibility, fecal fermentative metabolite concentrations, and large bowel microbial ecology of healthy adult cats. Journal of Animal Science 89:1376-1384 DOI 10.2527/jas.2010-3201.

Kieler IN, Mølbak L, Hansen LL, Hermann-Bank ML, Bjornvad CR. 2016. Overweight and the feline microbiome – a pilot study. Journal of Animal Physiology & Animal Nutrition (Berlin) 100:478-484 DOI 10.1111/jpn.12409.

Langille MGI, Zaneveld J, Caporaso JG, McDonald D, Knights D, Reyes JA, Clemente JC, Burkepile DE, Vega Thurber RL, Knight R, Beiko RG, Huttenhower C. 2013.
Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. *Nature Biotechnology* **31:**814-823 DOI 10.1038/nbt.2676.

Lozupone C, Knight R. 2005. UniFrac: a new phylogenetic method for comparing microbial communities. *Applied Environmental Microbiology* **71:**8228-8235 DOI 10.1128/AEM.71.12.8228-8235.2005

Lozupone CA, Hamady M, Kelley ST, Knight R. 2007. Quantitative and qualitative \( \beta \) diversity measures lead to different insights into factors that structure microbial communities. *Applied Environmental Microbiology* **73:**1576-1585 DOI 10.1128/AEM.01996-06

Middelbos IS, Vester Boler BM, Qu A, White BA, Swanson KS, Fahey Jr. GC. 2010. Phylogenetic characterization of fecal microbial communities of dogs fed diets with or without supplemental dietary fiber using 454 pyrosequencing. *PLoS ONE* **5**; e9768 DOI 10.1371/journal.pone.0009768.

Minamoto Y, Dhanani N, Markel ME, Steiner JM, Suchodolski JS. 2014. Prevalence of *Clostridium perfringens*, *Clostridium perfringens* enterotoxin and dysbiosis in fecal samples of dogs with diarrhea. *Veterinary Microbiology* **174:**463-473 DOI 10.1016/j.vetmic.2014.10.005.

Minamoto Y, Otoni CC, Steelman SM, Büyükleblebici O, Steiner JM, Jergens AE, Suchodolski JS. 2015. Alteration of the fecal microbiota and serum metabolite profiles in dogs with idiopathic inflammatory bowel disease. *Gut Microbes* **6:**33-47 DOI 10.1080/19490976.2014.997612.

Montalban-Arques A, De Schryver P, Bossier P, Gorkiewicz G, Mulero V, Gatlin DM 3rd, Galindo-Villegas J. 2015. Selective manipulation of the gut microbiota improves
immune status in vertebrates. *Frontiers in Immunology* 6:512 DOI 10.3389/fimmu.2015.00512.

Morgan XC, Huttenhower C. 2014. Meta'omic analytic techniques for studying the intestinal microbiome. *Gastroenterology* 146(6):1437-1448. DOI 10.1053/j.gastro.2014.01.049.

Navas-Molina JA, Peralta-Sanchez JM, Gonzalez A, McMurdie PJ, Vazquez-Baeza Y, Xu Z, Ursell LK, Lauber C, Zhou H, Song SJ, Huntley J, Ackermann GL, Berg-Lyons D, Holmes S, Caporaso JG, Knight R. 2013. Advancing our understanding of the human microbiome using QIIME. *Methods in Enzymology* 531:371-444 DOI 10.1016/B978-0-12-407863-5.00019-8.

Patra AK. 2011. Responses of feeding prebiotics on nutrient digestibility, faecal microbiota composition and short-chain fatty acid concentrations in dogs: a meta-analysis. *Animal* 5:1743-1750.

Panasevich MR, Kerr KR, Dilger RN, Fahey GC Jr, Guérin-Deremaux L, Lynch GL, Wils D, Suchodolski JS, Steer JM, Dowd SE, Swanson KS. 2015. Modulation of the faecal microbiome of healthy adult dogs by inclusion of potato fibre in the diet. *British Journal of Nutrition* 113:125-133 DOI 10.1017/S0007114514003274.

Rideout JR, He Y, Navas-Molina JA, Walters WA, Ursell LK, Gibbons SM, Chase J, McDonald D, Gonzalez A, Robbins-Pianka A, Clemente JC, Gilbert JA, huse SM, Zhou HW, Knight R, Caporaso JG. 2014. Subsampled open-reference clustering creates consistent, comprehensive OTU definitions and scales to billions of sequences. *PeerJ* 2:e545 DOI 10.7717/peerj.545.
Ritchie LE, Steiner JM, Suchodolski JS. 2008. Assessment of microbial diversity along the
feline intestinal tract using 16S rRNA gene analysis. *FEMS Microbiology Ecology*
66:590-598 DOI 10.1111/j.1574-6941.2008.00609.x.

Ritz K. 2007. The plate debate: cultivable communities have no utility in contemporary
environmental microbial ecology. *FEMS Microbiology Ecology* 60:358-362 DOI
10.1111/j.1574-6941.2007.00331.x

Rochus K, Janssens GP, Hesta M. 2014. Dietary fibre and the importance of the gut microbiota
in feline nutrition: a review. *Nutrition Research Reviews* 27(2):295-307 DOI
10.1017/S0954422414000213.

Rutz GM, Steiner JM, Bauer JE, Williams DA. 2004. Effects of exchange of dietary medium
chain triglycerides for long-chain triglycerides on serum biochemical variables and
subjectively assessed well-being of dogs with exocrine pancreatic insufficiency.
*American Journal of Veterinary Research* 65(9):1293-1302 DOI
10.2460/ajvr.2004.65.1293.

Schmitz S, Suchodolski JS. 2016. Understanding the canine intestinal microbiota and its
modification by pro-, pre- and synbiotics – what is the evidence? *Veterinary Medicine
and Science* 2:71-94 DOI: 10.1002/vms3.17.

Scott KP, Antoine JM, Midtvedt T, van Hemert S. 2015. Manipulating the gut microbiota to
maintain health and treat disease. *Microbial Ecology in Health & Disease* 26:25877 DOI
10.3402/mehd.v26.25877.

Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett WS, Huttenhower C. 2011.
Metagenomic biomarker discovery and explanation. *Genome Biology* 12:R60 DOI
10.1186/gb-2011-12-6-r60.
Song SJ, Lauber C, Costello EK, Lozupone CA, Humphrey G, Berg-Lyons D, Caporaso JG, Knights D, Clemente JC, Nakielny S, Gordon JI, Fierer N, Knight R. 2013. Cohabiting family members share microbiota with one another and with their dogs. *eLife* 2:e00458 DOI 10.7554/eLife.00458.

Sparkes AH, Papasouliotis K, Sunvold G, Werrett G, Clarke C, Jones M, Gruffydd-Jones TJ, Reinhart G. 1998. Bacterial flora in the duodenum of healthy cats, and the effect of dietary supplementation with fructo-oligosaccharides. *American Journal of Veterinary Research* 59:431-435.

Stecher B, Chaffron S, Käppeli R, Hapfelmeier S, Freedrich S, Weber TC, Kirundi J, Suar M, McCoy KD, von Mering C, Macpherson AJ, Hardt WD. 2010. Like will to like: abundances of closely related species can predict susceptibility to intestinal colonization by pathogenic and commensal bacteria. *PloS ONE* 6:e1000711 DOI: 10.1371/journal.ppat.1000711.

Suchodolski JS. 2011. Intestinal microbiota of dogs and cats: a bigger world than we thought. *Veterinary Clinics North America Small Animal Practices*. 41:261-272 DOI 10.1016/j.cvsm.2010.12.006.

Suchodolski JS, Dowd SE, Westermark E, Steiner JM, Wolcott RD, Spillmann T, Harmoinen JA. 2009. The effect of the macrolide tylosin on microbial diversity in the canine small intestine as demonstrated by massive parallel 16S rRNA gene sequencing. *BMC Microbiology* 9:210 DOI 10.1186/1471-2180-9-210.

Suchodolski JS, Dowd SE, Wilke V, Steiner JM, Jergens AE. 2012. 16S rRNA gene pyrosequencing reveals bacterial dysbiosis in the duodenum of dogs with idiopathic inflammatory bowel disease. *PLoS ONE* 7:e39333 DOI 10.1371/journal.pone.0039333.
Suchodolski JS, Foster ML, Sohail MU, Leutenegger C, Queen EV, Steiner JM, Marks SL. 2015. The fecal microbiome in cats with diarrhea. *PLoS ONE* **10**:e0127378 DOI 10.1371/journal.pone.0127378.

Suchodolski JS, Ruaux CG, Steiner JM, Fetz K, Williams DA. 2005. Assessment of the qualitative variation in bacterial microflora among compartments of the intestinal tract of dogs by use of a molecular fingerprinting technique. *American Journal of Veterinary Research* **66**:1556-1562.

Topol EJ. 2014. Individualized medicine from prewomb to tomb. *Cell* **157**:241-253 DOI 10.1016/j.cell.2014.02.012.

Vanhoutte T, Huys G, De Brandt E, Fahey Jr. GC, Swings J. 2005. Molecular monitoring and characterization of the faecal microbiota of healthy dogs during fructan supplementation. *FEMS Microbiology Letters* **249**:65-71 DOI 10.1016/j.femsle.2005.06.003.

Vitali B, Ndagijimana M, Cruciani F, Carnevali P, Candela M, Guerzoni ME, Brigidi P. 2009. Impact of a synbiotic food on the gut microbial ecology and metabolic profiles. *BMC Microbiology* **10**:4 DOI 10.1186/1471-2180-10-4.

Willard MD, Simpson RB, Delles EK, Cohen ND, Fossum TW, Kolp D, Reinhart G. 1994. Effects of dietary supplementation of fructo-oligosaccharides on small intestinal bacterial overgrowth in dogs. *American Journal of Veterinary Research* **55**:654-659.

Willard MD, Simpson RB, Cohen NH, Clancy JS. 2000. Effects of dietary fructooligosaccharide on selected bacterial populations in feces of dogs. *American Journal of Veterinary Research* **61**:820-825.
Wu GD, Chen J, Hoffmann C, Bittinger K, Chen YY, Keilbaugh SA, Bewtra M, Knights D, Walters WA, Knight R, Sinha R, Gilroy E, Gupta K, Baldassano R, Nessel L, Li H, Bushman FD, Lewis JD. 2011. Linking long-term dietary patterns with gut microbial enterotypes. *Science* **334**:105-108 DOI 10.1126/science.1208344.

Zoetendal EG, Akkermans ADL, de Vos WM. 1998. Temperature gradient gel electrophoresis analysis of 16S rRNA from human fecal samples reveals stable and host-specific communities of active bacteria. *Applied Environmental Microbiology* **64**:3854-3859.
Figure 1

Timeline of experimental design and sampling for 16S bacterial profiling (marked with *)

Two fecal samples were collected before (days -8 and -1) and during prebiotic administration (days 8 and 16). The prebiotic was administered daily to each animal for a period of 16 days (grey area).
Figure 2

Relative abundance of bacterial groups at the order level in trial 1

This figure displays column charts that show the relative abundance of 16S sequences at the order level for cats (A) and dogs (B). Samples were organized based on the highest abundant order (Clostridiales). Box plots for the most abundant orders are also shown (most bacterial groups did not show a statistical significant difference; see main text for details). The x axis contains the sample names (C=cats, D= dogs, numbers imply the number of the animal and the day of sampling (1=day -8, 2=day -1, 3=day 8, 4=day 16). For example, C13.3 implies cat number 13, day 8 during prebiotic administration.
Manuscript to be reviewed

A

B

Before During prebiotic
Before During prebiotic
Before During prebiotic
Before During prebiotic

Bacillales
Aeromonadales
Bifidobacteriales
Fusobacteriales
Coriobacteriales
Bacteroidales
Lactobacillales
Erysipelotrichales
Clostridiales
Figure 3

Relative abundance of bacterial groups at the order level for each cat and dog in trial 1

The sample names for cats (C) and dogs (D) are numbered depending on the animal ID (see Table 1). Bars represent day 8 and 1 before prebiotic day 8 and 16 during prebiotic administration, in that order. Please note that sample corresponding to day 8 during prebiotic administration in Dog 11 (D11) could not be analyzed.
Figure 4

Relative abundance of bacteria in cats in trial 1 before and during prebiotic administration

The LEfSe method revealed a significant difference in the relative abundance of Gammaproteobacteria (A) and Veillonellaceae (B) between the periods before and during prebiotic administration. Straight lines represent medians and dashed lines represent means.
Figure 5

Principal Coordinate Analysis (PCoA) plot

PCoA plot of weighted UniFrac distances in cats (trial 1). The lack of clustering by treatment was supported by ANOSIM and Adonis tests ($p>0.5$, see main text).

*Note: Auto Gamma Correction was used for the image. This only affects the reviewing manuscript. See original source image if needed for review.
Figure 6

Relative abundance of bacteria in dogs in trial 1 before and during prebiotic administration

The LEfSe method revealed a significant difference in the relative abundance of Staphylococcaceae (A) and Sutterella (B) between the periods before and during prebiotic administration. Straight lines represent medians and dashed lines represent means.
Figure 7

Principal Coordinate Analysis (PCoA) plot

PCoA plot of weighted UniFrac distances in dogs (trial 1). The lack of clustering by treatment was supported by ANOSIM and Adonis tests ($p>0.5$, see main text).

*Note: Auto Gamma Correction was used for the image. This only affects the reviewing manuscript. See original source image if needed for review.*
Figure 8

Relative abundance of bacterial groups at the order level in trial 2

This figure displays column charts that show the relative abundance of sequences at the order level for dogs (trial 2). Samples were organized based on the highest abundant order (Clostridiales). Box plots for the most abundant orders are also shown (most bacterial groups did not show a statistically significant difference; see main text for details). The x axis contains the sample names (D= dog, numbers imply the number of the animal and the day of sampling (1=day -8, 2=day -1, 3=day 8, 4=day 16). For example, D5.2 implies dog number 5 day -1 before prebiotic administration.
Figure 9

Relative abundance of bacterial groups at the order level for each dog in trial 2

The sample names are numbered depending on the animal ID (see Table 1). Within parenthesis, we also included the dog’s ID based on trial 1. Bars represent day 8 and 1 before prebiotic day 8 and 16 during prebiotic administration, in that order.
Figure 10

Relative abundance of bacteria in dogs in trial 2 before and during prebiotic administration

The LEfSe method revealed a significant difference in the relative abundance of *Dorea* (A), *Megamonas* (B), and Veillonellacea (C) between the periods before and during prebiotic administration. Straight lines represent medians and dashed lines represent means.
Table 1. Participant information (Trial 1, cats and dogs).

DSH: Domestic Short Hair.
Table 1. Participant information (Trial 1, cats and dogs). DSH: Domestic Short Hair.

| Cats IDs | Age               | Breed    | Final body weight |
|----------|-------------------|----------|-------------------|
| C2       | 4 years           | DSH      | 4.7 kg            |
| C3       | 1 year 6 months   | DSH      | 6.2 kg            |
| C4       | 6 years           | DSH      | 6.2 kg            |
| C5       | 8 years           | DSH      | 5.2 kg            |
| C8       | 2 years 6 months  | Tabby    | 4.2 kg            |
| C10      | 4 years           | Siamese mix | 5.1 kg         |
| C11      | 5 years           | DSH      | 5.1 kg            |
| C12      | 10 months         | Siberian | 5.7 kg            |
| C13      | 1 year 6 months   | Calico  | 2.8 kg            |
| C14      | 1 year 2 months   | DSH      | 4.0 kg            |

| Dogs IDs | Age               | Breed                             | Final body weight |
|----------|-------------------|-----------------------------------|-------------------|
| D3       | 1 year 5 months   | Doberman                          | 28.1 kg           |
| D4       | 10 years          | Rottweiler/Lab mix                | 33.3 kg           |
| D5       | 4 years           | Boston Terrier                    | 10.5 kg           |
| D6       | 1 year 6 months   | Lab                               | 25.3 kg           |
| D7       | 5 years           | Lab mix                           | 23.6 kg           |
| D8       | 4 years           | Mixed                             | 23.1 kg           |
| D9       | 7 years           | Weimaraner                        | 29.1 kg           |
| D10      | 1 year 10 months  | Pembroke Welsh Corgi              | 10.6 kg           |
| D11      | 7 months          | Mix hound/ Great Dane             | 25.6 kg           |
| D12      | 9 months          | Australian Kelpie                 | 16.0 kg           |
Table 2. Participant information (Trial 2, dogs only).

Table 2 (on next page)
1. **Table 2.** Participant information (Trial 2, dogs only).

| Dogs IDs | Age           | Breed            | Final body weight | Comments                  |
|----------|---------------|------------------|-------------------|---------------------------|
| D1       | 4 years 9 months | Boston Terrier   | 10.5 kg           | Same as D5 in Trial 1     |
| D3       | 8 years       | Weimaraner       | 29.5 kg           | Same as D9 in Trial 1     |
| D4       | 11 years      | Mix              | 30.4 kg           | Same as D4 in Trial 1     |
| D5       | 2 years 6 months | Doberman        | 29.5 kg           | Same as D3 in Trial 1     |
| D6       | 3 years 3 months | Mixed           | 29.5 kg           | New dog                  |
| D7       | 11 months     | Dutch Shepherd   | 20.4 kg           | New dog                  |
| D8       | 9 months      | Welsh Pembroke Corgi | 10 kg   | New dog                  |
| D9       | 1 year 9 months | Australian Kelpie | 18 kg   | Same as D12 in Trial 1   |
| D11      | 1 year 6 months | Australian Shepherd | 16.7 kg | New dog                  |
| D12      | 1 year 3 months | Pit Bull mix     | 32 kg            | New dog                  |